Parkinson's Repository of Biosamples and Network Datasets (Tracking Parkinson's)
- Conditions
- Parkinson's Disease
- Registration Number
- NCT02881099
- Lead Sponsor
- South Glasgow University Hospitals NHS Trust
- Brief Summary
Prospective observational study of Parkinson's disease with repeat clinical assessment and biobanking of blood samples.
- Detailed Description
To identify genetic and biomarker factors which affect the expression of Parkinson's Disease.
Primary objective: To define the severity and rates of progression of clinical features of Parkinson's Disease.
Secondary objective: To relate clinical phenomenology of Parkinson's disease to genetic and biomarker changes.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2614
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of participants with Parkinson's who have gene mutations and variations Up to 36 months Genotyping for leucine rich repeat kinase 2 (LRRK2), Glucocerebrosidase (GBA) (all cases) and Parkin, Phosphatase and tensin homolog-induced putative kinase 1 (PINK1)(onset\<50years)
- Secondary Outcome Measures
Name Time Method Categorisation of subtypes of Parkinson's using cluster analysis At 4 years Clustering of motor and non-motor features measured using Movement Disorder Society Unified Parkinson's disease rating scale (MDS-UPDRS), Montréal cognitive assessment (MoCA), Non-motor symptom Scale (NMSS), Scale for outcomes in Parkinson's autonomic (SCOPA-AUT), Olfaction testing using University of Pennsylvania Smell Identification Test (UPSIT) or Sniffin' sticks, and Leeds anxiety and depression scale (LADS).
This will use sequential factor analysis of the results of the above assessments, followed established methods, firstly exploratory factor analysis and secondly confirmatory factor analysis. Factor scores and other clinically important variables will then be combined to construct a single dataset for carrying out the cluster analysis. Hierarchical clustering will then be applied, and models with between 2 and 5 clusters will be described and compared.Proportion of cases with Parkinson's who have vascular comorbidity and risk factors At 4 years Prior history of vascular events, or calculated using Quantification of Risk version 2 (QRISK2) vascular risk score
Trial Locations
- Locations (1)
Department of Neurology, Queen Elizabeth University Hospital (Co-ordinating Centre)
🇬🇧Glasgow, Scotland, United Kingdom